Pyxis Oncology Inc

-0.09 (-4.84%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)77.65M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.83 Million
Adjusted EPS-$0.52
See more estimates
10-Day MA$1.87
50-Day MA$2.26
200-Day MA$2.40
See more pivots

Pyxis Oncology Inc Stock, NASDAQ:PYXS

321 Harrison Avenue, Suite 2, 8th Floor, Boston, Massachusetts 02118
United States of America
Phone: +1.617.221.9059
Number of Employees: 75


Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.